Comparative Pharmacology
Head-to-head clinical analysis: CLIMARA PRO versus DIETHYLSTILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLIMARA PRO versus DIETHYLSTILBESTROL.
CLIMARA PRO vs DIETHYLSTILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLIMARA PRO contains estradiol, an estrogen, and levonorgestrel, a progestin. Estrogens act by binding to nuclear receptors (ERα and ERβ) which act as transcription factors to regulate gene expression, leading to effects such as proliferation of the endometrium and relief of menopausal symptoms. Levonorgestrel is a progestin that induces endometrial transformation and shedding, counteracting estrogen-induced endometrial hyperplasia. The combination provides hormone replacement therapy with reduced risk of endometrial hyperplasia.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
One patch applied transdermally once weekly, delivering 0.05 mg estradiol and 0.25 mg levonorgestrel per day.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
The terminal elimination half-life of estradiol from Climara Pro (estradiol/levonorgestrel transdermal system) is approximately 2-3 hours for estradiol, but due to continuous transdermal delivery, steady-state concentrations are maintained with twice-weekly application. The half-life of levonorgestrel is longer, around 17-20 hours.
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Estradiol and estradiol valerate are metabolized primarily in the liver to estrone, estriol, and glucuronide/sulfate conjugates. Excretion occurs predominantly via the kidneys (>90% as conjugated metabolites), with less than 5% excreted unchanged in urine. Fecal excretion accounts for approximately 5-10%.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Category C
Category C
Estrogen/Progestin Combination
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."